世界の肉腫治療薬市場 – 業界動向と2030年までの予測

肉腫治療薬市場の分析と規模

国立がん研究所によると、米国の医師は2019年に約12,750件の軟部肉腫を診断し、5,270人がこの病気で亡くなると予想されています。しかし、治療と診断の技術進歩、および肉腫やその他の皮膚がんの発生率の上昇が市場の成長を牽引しています。さらに、発展途上地域での低コスト治療薬の需要の高まりは、市場の成長機会をもたらします。

データブリッジ市場調査は、2022年に12億2,220万米ドルであった肉腫治療薬市場は、2023年から2030年の予測期間中に9.00%のCAGRで成長し、2030年には24億3,531万米ドルに達すると予測しています。データブリッジ市場調査がまとめた市場レポートには、市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

肉腫治療薬市場の範囲とセグメンテーション  

Market Definition

Sarcoma is a type of cancer that can occur in any part of the body. Sarcoma begins in the bone and soft tissues and then spreads to other parts of the body. Although there are over 50 different types of sarcoma, they can be divided into two categories: soft tissue sarcoma and bone sarcoma, also known as osteosarcoma. Sarcoma is uncommon in adults. According to the American Society of Clinical Oncology, it accounts for about 1% of all adult cancers (ASCO). It is more prevalent in children, accounting for about 15% of all pediatric cancers.

Sarcoma Drugs Market Dynamics

Drivers

• Growing use of immunotherapy for the treatment of sarcoma

Stimulating or boosting the natural defences of a patient's immune system so that it works harder or smarter to find and attack cancer cells. Immunotherapy has recently become an important part of the treatment of certain types of cancer. New immunotherapy treatments and new ways of working with the immune system are being tested and approved at a rapid pace. Immunotherapy is more effective for some cancers than others. During the forecast period, these factors are expected to drive the growth of the sarcoma drugs market.

• Increasing Cancer Prevalence to support Sarcoma Drugs

Cancer has surpassed cardiovascular disease as the world's second leading cause of death. Environmental factors such as tobacco use, urbanization, changing dietary patterns, and an extended post-reproductive lifespan all contribute to this phenomenon.  Cancer is a growing burden, according to the World Health Organization (WHO), with the number of new cancer cases expected to rise from 18.1 million in 2018 to 29.4 million by 2040. As a result, rising cancer prevalence is expected to drive demand for global oncology cancer drugs during the forecast period. Furthermore, rising cancer awareness is expected to benefit the sarcoma drugs market in the coming years.

Opportunities

• Possession of a Strong Drug Pipeline to Fuel Sarcoma Drugs

Cancer treatment is evolving at a rapid pace. The R&D pipeline is producing a slew of novel treatments, many of which are frequently combined with other new or existing medications. Many pharmaceutical companies are investing in novel cancer drug research. For instance, Pfizer acquired Array BioPharma in 2019 with the goal of expanding its oncology presence and pipeline, beginning with an approved melanoma combination therapy that is currently in a phase 3 trial for a type of metastatic colorectal cancer. This, combined with an rising preference for biosimilar and biologics entering the market, is expected to propel the sarcoma drugs market forward.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained healthcare professionals who are unaware of the treatment methods for this disease may limit the growth of the global sarcoma drugs market during the forecast period.

This sarcoma drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the sarcoma drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2020, Junshi Biosciences, a global biopharmaceutical company, received FDA approval for Orphan Drug designation for toripalimab to treat soft tissue sarcoma. This approval is expected to assist the company in marketing new products and attracting new customers, resulting in increased revenue.

Global Sarcoma Drugs Market Scope

The sarcoma drugs market is segmented on the basis of type, drug therapy, drug type, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Angiosarcoma
• Epithelioid Sarcoma
• Liposarcoma
• Osteosarcoma
• Soft Tissue Sarcoma
• Kaposi's Sarcoma
• Chondrosarcoma
• Dermatofibrosarcoma Protuberans
• Leiomyosarcoma
• Others

Drug Therapy

• Chemotherapy
• Doxorubicin
• Epirubicin
• Ifosfamide
• Eribulin
• Temozolomide
• Methotrexate
• Others
• Targeted therapy
• Olaratumab
• Imatinib
• Pazopanib
• Pexidartinib
• larotrectinib
• Others
• Immunotherapy
• Pembrolizumab
• Others

 Drug Type

• Branded
• Lartruvo
•  Gleevec
• Votrient
• Tazverik
• Turalio
• Vitrakvi
• keytruda
• Others
• Generic

 End-Users

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

 Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Sarcoma Drugs Market Regional Analysis/Insights

The sarcoma drugs market is analyzed and market size insights and trends are provided by country, type, drug therapy, drug type, end-users and distribution channel as referenced above.

The countries covered in the sarcoma drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the sarcoma drugs market due to the presence of high healthcare expenditure and favourable reimbursement policies for the treatment.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to constant rise in the incidence of cancer coupled with increased demand for cost-efficient therapeutics.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The sarcoma drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for sarcoma drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the sarcoma drugs market. The data is available for historic period 2011-2021.

Competitive Landscape and Sarcoma Drugs Market Share Analysis

The sarcoma drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to sarcoma drugs market.

Some of the major players operating in the sarcoma drugs market are:

• Johnson & Johnson Private Limited (U.S.)
• Abbott (U.S.)
• アッヴィ社（米国）
• バウシュ・ヘルス・カンパニーズ（カナダ）
• サン・ファーマシューティカル・インダストリーズ（インド）
• オーロビンドファーマ（インド）
• ルピナス（インド）
• ヒクマ・ファーマシューティカルズPLC（英国）
• アムニール・ファーマシューティカルズLLC（米国）
• ファイザー社（米国）
• マイランNV（米国）
• ブリストル・マイヤーズスクイブ社（米国）
• GSK plc. (英国)
• バイエルAG（ドイツ） 

SKU-57035